The Federal government may seek to overturn conflicting ACT laws, as Commonwealth law prohibits possession of cannabis.

The IDAT Program is an option of last resort for those in NSW who are dealing with severe substance dependence.

To ensure that children are not exposed to risk of harm, the Court may order that parents undertake random drug testing.

An understanding of the regulatory landscape is necessary before attempting any commercial activities for cannabis.

Companies must comply with not only the Australian Consumer Law but also the Therapeutic Goods Advertising Code.

Many countries are tightening regulations to assist consumers to make informed and healthier food and beverage choices.

E-cigarette industry continues to grow as controls are fail to protect young Australians from immediate & future health harms.

This article explains laws in Queensland surrounding the industrial hemp industry for current or potential participants.

NSW supermarkets are now introducing labels which display the average kilojoule content of all ready-to-eat food items.

The implementation of the recommendations may deliver significant benefits to medicine and medical device industries.

An expert panel will review the "appropriateness of the extension arrangements for pharmaceutical patents" in Australia.

The Therapeutic Goods Act does not curtail any person's (or the Government's) right to recover on the usual undertakings.

Hedging their bets, the patentees filed two alternative applications to extend the term of the Patent – one based on KEYTRUDA and the other based on OPDIVO.

Proposed changes will impact brand owners in the pharmaceutical industry, restricting IP in packaging and labelling.

The TPPA-11 is what remains of the Trans-Pacific Partnership (TPP) Free Trade Agreement following the US withdrawal.

This legislation aims to strengthen ASADA's investigative functions and to enhance its information sharing arrangements.

This one’s succinct but very important for those interested in the interplay between IP strategy and government regulatory control or pharmaceuticals in the USA.

Australia's pharmaceutical patent landscape has reached a critical juncture, with appellate courts reconsidering fundamental principles of patent scope, term extensions, and remedies that will shape originator-generic disputes for the foreseeable future. As the High Court prepares to rule on patent term extensions for formulation patents and new Federal Court practice directions take effect, the strategic calculus for both innovators and generic entrants is being fundamentally rewritten.

The article explores the differences between the two types of products and how to navigate the regulatory requirements.

Following QPBO Act changes, here sets out what steps should be taken now depending on how a pharmacy business is currently structured.